Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Longer survival with tagraxofusp versus venetoclax in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): Results of a real-world analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

ASAnthony S. SteinHLHannah Levavi

Discussion

Loading...

Member takes

Overview

Observational analysis found longer overall survival in BPDCN patients treated with tagraxofusp versus venetoclax, indicating its potential as a first-line therapy.

Key Points

  • Longer median overall survival of 35.3 months with tagraxofusp compared to 10.5 months with venetoclax highlights its efficacy.
  • The study analyzed data from 94 patients, 47 each on tagraxofusp and venetoclax, assessing various treatment regimens.
  • Kaplan-Meier methodology was employed to estimate overall survival, accounting for patient characteristics and treatment details.
  • These findings support tagraxofusp as standard of care for blastic plasmacytoid dendritic cell neoplasm patients, especially in first-line settings.

Cite This Study

Stein et al. (2025) studied this question.

synapsesocial.com/papers/69362f3a4fa91c937236d3a3https://doi.org/10.1182/blood-2025-4612
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Tagraxofusp, azacitidine, and venetoclax (TAG-AZA-VEN) triplet therapy shows efficacy, tolerability, and transplant potential in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): Results of a phase 2 trial2025 · 4 citations
  2. 2Real-world use of venetoclax and hypomethylating agents (HMA) in blastic plasmacytoid dendritic cell neoplasm (BPDCN): A multi-institutional case series2025
  3. 3Real-world study of treatment landscape and safety outcomes of US patients with blastic plasmacytoid dendritic cell neoplasm2025 · 1 citations
  4. 4Blastic plasmacytoid dendritic cell neoplasm (BPDCN) international registry: Assessment of the allo-HCT outcomes2025 · 1 citations
  5. 5Real-world study of tagraxofusp monotherapy in relapsed or refractory blastic plasmacytoid dendritic cell neoplasm2025